differenti cro powerhous superior
life scienc tool diagnost initi
initi outperform target price third largest global contract research
organ cro offer preclin clinic central laboratori servic
highli lever healthi industri fundament across biopharmaceut landscap
serv top biopharma compani global well small- mid-siz
custom biotech compani increment driver expand biotech
exposur uniqu patient enrol solut differenti laboratori servic
offer support high-single-digit low-double-digit revenu growth
earn compound-annual-growth-rate
strateg focu support high qualiti growth particip billion
cro market grow compound-annual-growth-rate pharma sponsor continu invest
 outsourc greater portion independ servic provid ppd
growth outpac market view leverag size scale well
multipl co-specif driver first biotech re-launch expand
exposur faster-grow higher-margin sub-market also provid custom
diversif meanwhil acceler enrol solut offer address
key drug develop pain point patient recruit drive new busi win
high-growth laboratori servic sale also drive acceler growth
yr compound-annual-growth-rate compel cross-sel opportun one-third biotech win co-sel
clinic develop encouragingli despit invest drive growth
maintain industri averag margin profil dynam view sustain
driven price disciplin on-going effici initi
valuat risk share vs sinc februari
ipo trade price-to-earnings ev/ebitda valuat fulli
reflect aforement growth driver view target price predic
price-to-earnings ev/ebitda multipl respect premium
cro peer group respect better reflect compel above-
market revenu growth sustain heighten margin profil risk fluctuat
spend cancel regulatori shift leverag net debt/ltm ebitda estimate
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
largest global contract research organ includ
preclin clinic central laboratori servic serv top
biopharma compani global well variou small/mid-s
predic better anticip book across biotech
acceler enrol solut well faster growth across
laboratori servic busi conjunct strengthen
predic slight deterior underli market fundament
compound slower anticip book across biotech
acceler well slower anticip
growth laboratori servic busi
 close
tabl content
clinic develop servic revenu
laboratori servic servic revenu
dig ppd backlog book dynam
error bookmark defin
earn outlook financi resourc
exclud preclin central laboratori post-approv
initi coverag outperform rate target price
largest global contract research organ cro includ preclin clinic
central laboratori servic market employe ou
offic across countri serv top biopharmaceut compani global
well variou small- mid-siz custom biotech compani gener
billion revenu year-over-year
found fred eshelman one-person consult firm scale nice
becom one largest global launch initi public stock offer
sever year public market acquir affili carlyl group
hellman friedman all-cash transact valu billion
privat held complet notabl acquisit includ acurian evidera
million well establish acceler enrol solut offer
alongsid renew focu rapidli expand biotech arena januari
publicli file launch second ipo process share price vs initi
rang februari impli billion market cap
favor industri tailwind particip billion cro market includ
discoveri preclin develop clinic develop central laboratori
expect grow compound-annual-growth-rate biopharmaceut compani
continu invest research develop outsourc greater portion
independ servic provid estim clinic develop outsourc
today metric expect reach cost complex
biopharmaceut drug develop rise increasingli oner reimburs
regulatori environ lead biopharmaceut sponsor seek effici flexibl
develop solut via cro partner expect total spend grow
compound-annual-growth-rate driven larg pharmaceut compani faster-
grow biotechnolog compani leverag sophist scientif capabl
discov develop commerci new therapeut address critic unmet need
also believ benefit follow increment driver
expand exposur strateg posit lead partner
biotech arena target biotech offer re-launch allow
capit underli market shift wherebi rate biotech spend
growth meaning outpac larg pharma biotech account
new drug approv past five year late-stag pipelin
vs term exposur backlog associ biotech
vs compar favor rel competitor time
expect biotech exposur expand contribut diversifi
custom base top custom revenu also potenti acceler
growth across clinic develop segment
uniqu patient enrol solut enhanc studi start win rate
acceler enrol solut address key pain point across drug
develop continuum includ patient recruit studi start also
provid import sourc differenti rel peer innov solut
util global dedic site network research site locat across five
contin countri combin acurian databas fulli identifi
consent patient inform view offer key competit
advantag across increasingli import area focu biopharma custom
enhanc valu proposit therebi support new busi win effort moreov
may also offer stand-alone basi site patient access market
diversifi revenu stream well addit mechan develop new/exist
custom relationship offer upsid estim
sell opportun integr global laboratori servic offer net
servic revenu complement core clinic develop servic busi offer
gmp bioanalyt biomark vaccin central laboratori solut sever
oper central laboratori potenti esoter test bioanalyt
capabl maintain comprehens solut increment
advanc laboratori offer provid key competit advantag estim
laboratori servic offer continu grow acceler rate estimate
next five year notabl custom frequent cite laboratori servic
key rational partner cro one-third win co-sel
clinic develop lab servic demonstr inher busi unit synergi
consist attract margin profil boast oper margin
meaning industri averag attribut
part rigor price disciplin contract bid dilig cost contain effort
consist focus product effort includ util resourc
manag zero-bas budget technolog invest global hub talent
lower cost geographi encourag sustain heighten margin
profil even despit invest across employe base includ headcount growth
support new busi retent effort
deploy remain key growth stori net debt ebitda follow
ipo expect like priorit debt pay target net leverag
longer term estim debt pay expect also
continu priorit invest across core platform order support longer term
growth regard capit deploy includ organ invest strateg
 potenti also return capit sharehold via share repurchas
valuat share vs sinc februari
ipo share current trade price-to-earnings ev/ebitda
valuat fulli reflect aforement growth driver view contribut
outperform rate target price predic price-to-earnings
ev/ebitda multipl respect premium cro peer group
respect driven aforement company-specif opportun drive above-market
growth sustain height margin profil longer term
risk factor risk call includ fluctuat spend deterior
project delay chang scope shift pipelin regulatori shift drug price scrutini
leverag implic foreign currenc fluctuat capit deploy miscu
figur share price perform ipo date
common share offer basic share includ green shoe offer vs propos rang ipo million- redeem million initi holdco notes- redeem million addit holdco notes- excess net proce use gener corpor purposes- investor incl green shoe carlyl investor incl green shoe spectrum investor incl green shoe gic investor incl green shoe use proce control vs pipo price charl martineau pm univers toronto march
largest global contract research organ cro includ preclin clinic
central laboratori servic well largest clinic cro provid billion
sale predominantli focus deliv phase i-iv clinic develop
laboratori servic pharmaceut biotechnolog medic devic govern
organ well industri particip support custom effort bring
new medicin market around world employe ou
offic across countri serv top biopharmaceut compani
global well variou small- mid-siz custom past five year
impress conduct clinic trial laboratori work
compound estim total address cro market opportun worth
billion grow mid-singl high-singl digit annual growth rate continu
exceed time
found fred eshelman one-person consult firm scale nice
becom one largest global launch initi public stock offer
acquir medic research laboratori intern ad central lab servic
north america europ middl east africa total revenu exceed
billion first time headcount exceed sever year
public market acquir affili carlyl group hellman
friedman all-cash transact valu billion privat held
notabl acquir acurian full-servic provid clinic trial patient enrol retent
solut evidera lead provid evidence-bas solut
million addit establish acceler enrol solut offer
combin patient data network clinic research site januari
publicli file launch second ipo process share price vs rang
februari impli billion market cap
figur annual total revenu revenu growth
basi
figur annual ebitda ebitda margin net
estim gener billion total revenu basi
includ billion net servic revenu basi slight year-over-
year margin degrad new public compani cost revenu basi ppd
top custom repres less revenu top custom repres
total revenu indic still fairli concentr custom base larg pharma
continu domin said expect revenu concentr diminish longer term
continu gain traction differenti emerg biotech offer
serv biotech compani meanwhil therapeut basi broadli
expos oncolog hematolog backlog chronic diseas neurolog
figur backlog therapeut area
note revenu base basi
note backlog base basi
two report unit distinguish function includ clinic develop
sale laboratori servic clinic develop servic includ phase i-
iv develop peri- post-approv site patient access servic
laboratori servic includ rang high valu advanc test servic beyond central lab
servic typic offer importantli offer servic custom
varieti commerci model includ full-servic function servic partnership
albeit smaller mix million rang recent
began focu grow share space
figur annual servic revenu revenu growth
figur net servic revenu mix
clinic develop servic revenu
compet billion clinic develop industri compris
phase i-iv clinic servic market grow mid-singl high-singl digit
notabl also maintain offer peri- post-approv market
size billion opportun annual well billion
patient access servic market expect outpac broader
clinic cro market longer term lead global outsourc partner scale share
captur like smaller limit therapeut geograph scope note
conduct clinic trial past five year multipl award
industri thought-lead recogn excel clinic research qualiti thereon
expect gener million net servic revenu growth
year-over-year nice outpac market
figur clinic develop servic revenu revenu growth
offer comprehens solut custom full develop life-cycle expertis
address client need includ product develop consult servic earli
peri- post-approv servic medic commun highlight offer servic
depth
product develop consult servic team physician scientist
regulatori profession biostatistician pharmaceut expertis develop
integr product develop strategi biopharmaceut client includ
interdisciplinari preclin chemistri manufactur control well clinic
regulatori road map develop product offer special guidanc across
major therapeut area includ oncolog cardiovascular diseas neurolog
psychiatri infecti diseas rheumatolog metabol diseas
earli develop servic three facil texa clinic nevada
hospital-adjac facil florida hospital-adjac facil
provid support earli clinic develop program includ phase trial
supplement facil global network affili clinic trial site
includ nine us nine intern site locat associ
univers and/or hospit also complement earli develop offer
acurian patient recruit tool well special servic team provid
pharmacolog medic write regulatori pharmacovigil support
conduct clinic pharmacolog phase studi past five year
maintain solid track record deliver time
phase ii-iv clinic trial manag provid clinic trial manag
phase ii-iv studi investig new drug biolog medic devic
varieti outsourc model includ tradit full-servic model provid
substanti servic well function servic provid model
provid specif servic function offer includ protocol design clinic trial
strateg feasibl investig site select project manag site studi start-up
activ clinic monitor data captur data manag biostatist safeti
medic monitor pharmacovigil regulatori affair medic write global clinic
suppli eclin servic qualiti assur virtual trial solut term
therapeut area extens expertis across oncolog hematolog
gastroenterolog rare diseas chronic diseas urolog vaccin
note provid clinic trial servic nation institut allergi
infecti diseas niaid specif focu aid us govern
research prioriti includ develop vaccin zika viru
acceler patient recruit process trial start-up global dedic site
network extend across five contin countri complement acurian
databas fulli identifi consent inform deliveri model
support even replac tradit site select model patient recruit
remain key pain point biopharmaceut compani repres one
meaning cost bottleneck develop explor valu
solut detail page model repres meaning sourc
differenti cro key rational posit bia stock
peri- post-approv servic scientist consult
special conduct real-world patient-cent health econom epidemiolog
market access research provid real-world research evidence-bas
solut order demonstr real-world effect safeti valu
pharmaceut engag custom earli develop cycl order
cultiv evid strategi continu provid scientif expertis insight
loss exclus help foster stickier custom relationship develop
evid drug therapi annual across countri well
support numer payer submiss includ revers decis uk
nation institut excel
medic commun employ health care profession includ
physician pharmacist nurs life scienc graduat servic inbound
outbound peri- post-approv contact center provid medic technic
inform custom patient support portfolio product local
languag expertis global scale maintain custom contact center
across major market includ north america latin america europ asia-pacif
locationfacility-typenumb bedstyp patientsdetailsaustin earli phase clinic pharmacolog trial expertis first-in-human sad/mad bioavailability/bioequival drug-drug interact food effect thorough qtcla vega nevadahospital-adjac facil volunt patientssupport clinic research first-in-human proof-of-concept trial special emphasi metabol studiesorlando floridahospital-adjac facil volunt patientsrec acquir dedic phase research special focu charl martineau pm univers toronto
product qualiti complaint manag market program support patient adher
clinic trial support product recal crisi manag past year
support product launch manag million medic
inform inquiri document million advers event product
laboratori servic servic revenu
also compet billion laboratori servic industri compris
billion central laboratori market billion advanc laboratori test market
laboratori servic market altogeth expect grow averag
year expertis consist outpac broader market
achiev compound-annual-growth-rate sinc dynam expect endur continu invest
differenti servic particularli across biolog special test note
current serv biotech custom among larger compani
squar feet laboratori space includ two gmp facil two bioanalyt
biomark lab one vaccin facil four central lab global expect
gener million laboratori servic revenu growth year-over-year
figur laboratori servic revenu revenu growth
laboratori servic offer support team dedic
scientist includ advanc degre scientist phd md focus
invest scientif expertis support industri advanc includ
develop new bioanalyt assay valid new gmp assay
also support larg molecul project biosimilar project
biomark studi past five year
figur lab servic scientif employe base mix advanc degre
importantli laboratori offer includ central laboratori servic
typic offer broader diversifi also advanc laboratori test
includ gmp bioanalyt biomark vaccin servic notabl differenti rel
outsourc constitu highlight offer servic depth
gmp year experi space provid high-qual chemistri
manufactur control pharmaceut laboratori test servic follow
current good manufactur practic cgmp type pharmaceut product
across small molecul biolog includ activ pharmaceut ingredi
api drug product inhal product medic devic core compet
includ method develop optim valid transfer qualiti control qc
test product stabil in-process in-us releas extract leachabl full
program support microbiolog evalu physiochem character
estim top three provid alongsid labcorp eurofin
squar feet purpose-built laboratori space well employe
bioanalyt biomark lab bioanalyt lab measur drug metabolit
immun respons live organ experi across small molecul
biolog vaccin biomark specif bioanalyt lab help
develop compound past five year meanwhil also
maintain biomark lab help client identifi appropri biomark target
therapi develop select right regulatori approach fit-for-purpos full
complianc select appropri analyt methodolog develop valid specif
assay confirm intend use purpos clinic trial importantli
dedic biomark lab addit capac integr bioanalyt central
lab enabl flexibl develop strategi custom project tier
regulatori strategi also allow leverag scientif expertis across
experi assay develop qualif valid year experi
provid special statist support servic nine year relat provid cell-
base assay servic specif vaccin develop also support
approv fda-approv vaccin past five year demonstr robust
regulatori knowledg expertis offer aim evalu efficaci vaccin
molecular assay pcr sequenc serolog assay elisa/eia/hai msd
electrochemilumines multiplex cell-bas function assay
immunospot serum bactericid assay importantli offer integr
vaccin solut wherebi special vaccin lab clinic research team
close collabor ensur sampl process track data report well-
central laboratori central lab support collect transport test
analysi clinic trial sampl aim measur safeti efficaci
ppd central lab offer includ anatom patholog autoimmun inflammatori
allergi test biostorag cell-bas assay flow cytometri chemistri
immunoassay chromatographi mass spectroscopi genom molecular assay
hematolog coagul microbiolog oncolog protein analysi urinalysi
data regulatori requir becom increasingli detail complex view
biopharma custom increasingli outsourc central laboratori work vs maintain
invest intern capabl labcorp covanc remain largest central lab
ahead iqvia joint ventur solut grow
double-digit rang well industri growth level indic success take
share albeit like larg part smaller central lab limit geograph
notabl increasingli integr solut provid comprehens full-
servic offer exampl offer preclaru central lab databas
enterpris inform manag system deliv central lab data client
real time enabl central lab result automat integr
patient/med data clinic trial manag system therebi support
faster patient enrol inform decision-mak faster respons critic
valu advers event
dig ppd backlog book dynam
backlog metric repres key area focu baromet perform cro
industri includ backlog convers book-to-bil cancel rate
clinic trial becom complex backlog shift therapeut area patient
recruit difficult timelin prolong backlog convers may slow
consist recent industri commentari trend way exampl one
activ therapeut area recent oncolog repres singl largest area
focu clinic develop today spend oncolog medicin total billion
world-wide y/i fifth consecut year double-digit growth accord
iqvia insight categori spend project exceed billion
compound-annual-growth-rate moreov late-stag oncolog pipelin includ molecul
repres increas sinc rise focu target therapi
particular relev grow exposur complex studi
emerg therapeut area oncolog complex therapeut area
often longer start-up patient recruit timelin oncolog instanc
increas number patient recruit special center mani use
central ethic committe review board lead longer start-up time identifi
patient highli target rare indic also contribut prolong start-up
period underscor valu proposit data-enrich model potenti
improv overal trial recruit process drive effici across drug
backlog convers metric alon alway compar histor
lag industri backlog convers perspect trend improv
past year essenti converg industri averag evolut like driven
primari factor inclus laboratori servic backlog repres
billion inher faster burn rate clinic develop compound
acceler growth profil across lab platform vs clinic develop
stabil biotech offer follow busi model transit
de-standard book metric wherebi industri constitu report
basi vs book metric obscur compar go
forward expect backlog convers improv albeit slow pace laboratori
servic busi becom greater portion backlog continu drive
effici clinic develop platform
figur backlog convers converg industri averag
note industri averag adjust vari definit recognit backlog less aggress depend compani
book-to-bil ratio gener remain threshold perceiv
healthi basi acknowledg signific volatil
time-frame way background origin biotech focus function
wave meaning fund smaller biopharma compani pull-back
spend across larg pharma constitu biotech busi progress
fairli well manag revamp busi order enhanc servic
better tap rapidli grow market opportun see detail expand biotech
exposur page result current biotech offer busi model
evolut decis account two-third year-over-year deterior net book
higher rate cancel vs histor averag also contribut
weaker net book
importantli start constitu requir adopt revenu recognit
standard refer compani requir estim contract
revenu use contract cost incur date includ reimburs cost measur
project revenu vs previou methodolog includ reimburs cost said
report metric across industri particip remain vari book perspect
exampl iqvia health labcorp covanc report book metric
basi icon plc syneo health medpac report basi
differ report method inher skew compar result higher
averag book-to-bil healthi threshold vs albeit meaning
higher quarter-to-quart volatil due pass-through revenu trail
twelv month book bill ratio notabl industri averag like less compar
continu highlight book remain healthi estim net book
bill robust trend view
conversionindustri averag backlog conversionindustri averag mix charl martineau pm univers toronto march
note industri averag adjust vari definit recognit backlog less aggress depend compani
context highlight differ book polici across larger diversifi
figur recogn book as-award perspect vs contract
as-award polici seem less conserv as-contract polici first glanc
note report as-award methodolog actual maintain higher backlog
convers rate rel as-contract counterpart moreov note haircut
valu book put backlog averag depend upon specif
contract area enhanc conservat book polici also highlight
book includ laboratori servic busi current billion backlog key
differ methodolog rel cro peer typic includ clinic
develop busi core book metric
figur ad perspect differ book polici also effect compar
parexel metric base disclosur exposur measur percentag clinic develop revenu
moreov note organ revenu growth potenti predic upon book-to-bil
metric backlog convers rate accord analysi assum stabl convers
book billindustri averag ttm book billindustri averag mix ratepolicyiqv as-contracted-clin onlyful valueful day prior project stay backlog unless cancel client cost-bas input methodmedp as-awardedonli includ enu gener backlogclin onlythre day prior new busi quarterli studi amount year includ backlog as-awardedwithin monthsclin onlyful month day prior notic -- -must receiv formal contract letter interest loi vs verbal commit synh as-awardedwithin monthsclin commerci report separ full month day prior criteria customer/project fund award conting intent enter contract project start time prah as-awarded-clin onlyful day prior studi remain backlog determin regard statu made compani iclr as-awarded-clin onlyful valu current month day prior multi-phas trial add current phase revenu backlog ppd as-awardedwithin monthsclin laboratori servicesful yearsnot day prior award valu given haircut base histor experi reduct averag lh cvd as-contractedwithin twelv monthsclin onlyful monthsnot volum commit contract rang year revenu recogn end period tickera award vs contractedtim enu generatingtyp book backlog conversionttm net btb net btb cancellationsservic typeaccount conventiontim report new charl martineau pm univers toronto march
rate estim third highest organ growth potenti book-to-bil
offer pathway growth line compani commentari view look
book-to-bil backlog convers conjunct help provid normal
framework particularli consid varianc discrep across cro book polici
said also acknowledg limit exercis dynam potenti
play well year-over-year comp
figur organ growth compon book-to-bil backlog convers
compet primarili larg clinic scale includ icon
plc health scienc syneo health covanc subsidiari labcorp medpac
hold parexel among numer specialti region well in-hous
drug develop divis sponsor custom lesser extent also compet
charl river laboratori largest preclin outsourc provid
rel peer group outpac larger diversifi clinic
revenu growth standpoint also boast healthi margin profil despit meaning
organ invest function disciplin cost structur manag
increas focu small- mid-siz biopharma arena compani typic
figur revenu cro player million
pre-clin clinic central laboratori servic
note covanc cvd subsidiari laboratori corpor america
org growthttm book-to-billavg clinic researchasc covanceasc clinic solutionsasc rdsasc ratecompani report metricsaccount conventionimpli organ enu growth potenti assum stabl convers btb health plc river enueclin charl martineau pm univers toronto march
broader industri averag
ahead larg diversifi clinic
note covanc cvd subsidiari laboratori corpor america
note covanc cvd subsidiari laboratori corpor america
figur industri overview scope cro capabl
figur competit landscap summari point differenti
iqvia world largest cro lead healthcar inform technolog servic
compani form merger im health quintil octob
gener billion revenu scope offer span clinic drug
develop commerci life-cycle support pharmaceut biotechnolog medic
devic health care custom research develop solut rd platform
repres revenu compet head-to-head serv relev
constitu phase i-iv trial iqv technolog analyt solut segment
slightli less relev stand-alone basi note increasingli
use data enhanc patient recruit integr offer billion win to-
date emb custom workflow orchestr custom
billion revenu fourth largest cro ex-post approv largest
contract commerci organ global form merger inc research
inventiv health august differenti comprehens scope
servic span clinic develop post-approv commerci offer fairli
larg commerci outsourc busi revenu develop integr
servic syneo one offer end-to-end clinical/commerci solut to-dat
billion busi end-to-end win ad million book
laboratori corpor america lh outperform
billion total revenu labcorp lead nation clinic laboratori provid
revenu compet larg nation player independ
region lab hospital-affili laboratori physician-own laboratori relev
lh acquir lead cro covanc drug develop februari
busi repres total revenu covanc provid end-to-end drug
develop early-stag research clinic develop commerci market access
biopharmaceut medic devic diagnost compani importantli lh maintain
meaning presenc across central lab market given core busi clinic laboratori
diagnost note lh acquir envigo preclin research servic busi
sold covanc research product busi envigo order support growth
across broader cro landscap
origin found ireland iclr gener billion revenu impli
estim share broader cro market focus primarili phase ii-iii
outsourc compani also expand organ acquisit offer full
companykey point differentiationia player clinic develop uniqu global data asset im health merger icon plc iclr higher custom concentr network strategi net cash posit high roic inc clinic outsourc servic support differenti laboratori offer enrol solut mid-siz cro flexibl solut focu via strateg solut group sale syneo health uniqu end-to-end platform offer clinic trial servic full commerci commerci sale medpac hold scientifically-driven full-servic approach uniqu emerg biopharma exposureparexelmid-s privat cro differenti technolog solutionscharl river laboratori global leader preclin anim research charl martineau pm univers toronto march
rang clinic servic resourcing/staf solut central laboratori estimate revenu
bioanalyt servic commercialization/outcom research consult earli phase
phase support iclr maintain central lab relat work importantli icrl aim
enhanc patient recruit site network strategi vs data focus solut
view meaning support studi start-up still earli day
revenu iclr remain optimist prospect differenti dedic research
doctor relev site traction begin manifest util build across
top five custom note iclr believ need data order provid
relev meaning insight custom
billion revenu fifth largest cro offer clinic drug develop
servic biopharmaceut compani servic offer expand includ
function across phase clinic drug develop process built scale
significantli acquisit name acquisit symphoni health well
cromedica broad array servic span develop stage offer
project-bas servic phase iv well function outsourc servic
strateg solut group differenti includ exposur
well peer percentag revenu well data strategi via symphoni
acquisit acceler patient recruit note central lab
estim parexel gener billion revenu impli seventh largest cro
parexel integr solut span drug develop phase well relev
access life-cycle manag core clinic research segment focus aspect
clinic develop informat busi offer integr platform applic
clinic data servic aim enhanc overal drug develop speed accuraci effici
remind parexel acquir pamplona capit manag privat equiti firm
june billion ltm ebitda
billion revenu lead cro focus preclin discoveri
early-stag develop new product pharmaceut biotechnolog compani
govern agenc academ institut world-wide global leader breed
distribut research model busi support broader portfolio
preclin manufactur servic area particip intern
develop well acquisit expand develop comprehens
portfolio discoveri safeti assess servic well exposur
discoveri albeit limit note inher less relev comp given skew
toward preclin early-stag develop
billion revenu smallest publicli trade cro found
dr august troendl medp growth larg organ model differenti
highli disciplin exclus full-servic model inher skew small- mid-
size biotechnolog custom revenu vs larger biopharma custom
conduct clinic trial across major therapeut categori area strength
includ cardiolog metabol diseas oncolog endocrinolog anti-vir anti-
infect avai select therapeut expertis medic devic
overal cro market includ discoveri preclin clinic develop central
laboratori worth estim billion current expand billion
compound-annual-growth-rate biopharmaceut compani continu invest outsourc
greater portion independ servic provid estim clinic
develop outsourc today metric expect reach cost
complex biopharmaceut drug develop
reimburs regulatori environ lead biopharmaceut sponsor seek
effici flexibl develop solut via cro partner expect total spend
grow compound-annual-growth-rate driven larg pharmaceut compani
faster-grow biotechnolog compani leverag scientif advanc discov
develop commerci new therapeut address critic unmet health need
estim
accord evaluatepharma spend grown compound-annual-growth-rate sinc
world-wide expenditur
biopharmaceut compani billion reach billion
billion address market spend driven multipl industri
dynam includ rise demand treatment complex rare diseas well
increas complex clinic develop process addit driver increas
 spend outsourc includ challeng commerci product
includ increas regulatori scrutini market strategi expand role payor
govern reimburs pressur increasingli oner regulatori requir post-
approv monitor studi prolifer specialti target nich
figur global research develop spend
figur clinic cro market outsourc
figur highlight cro market model outlin assumpt market
growth sub-seg penetr includ discoveri preclin develop safeti
clinic develop phase i-iv central laboratori servic
 pipelin continu expand across phase clinic trial
start increas year-over-year compound-annual-growth-rate notabl growth
across phase ii oncolog trial therapeut area oncolog trial start rose
gi/nash increas pipelin continu target inher complex area
phase number phase ii trial start rose phase
rel flat outsiz exposur oncolog continu well-posit
momentum oncolog trial start view note exposur percent
backlog septemb basi oncology/hematolog
cagrglob outsourc projectionsglob develop spend research spend global research develop develop research cro address discoveri outsourc research outsourc address research develop research cro address market prehuman develop develop phase i-iv lab cro address prehuman develop develop phase i-iv cro market prehuman develop develop phase i-iv lab cro market prehuman develop develop phase i-iv lab cro charl martineau pm univers toronto march
figur trial start phase growth led phase ii
specif accord iqvia pipelin intellig number molecul late-
stage clinic develop pipelin phase ii later reach rise year-
over-year follow compound-annual-growth-rate sinc number oncolog
molecul primari driver account pipelin growth
repres current late stage pipelin product gi therapi
experienc growth sinc repres pipelin total
product due expans nash pipelin neurolog therapi account
pipelin grown past five year pain product
dermatolog smaller proport pipelin grown sinc
note pain product may experi slower growth near-term greater scrutini amidst
opioid crisi meanwhil infecti diseas vaccin grew respect
past five year notabl slower therapeut area
next-gener biotherapeut ngb cell gene nucleotid therapi account
overal pipelin doubl number sinc reach
compound end vs acknowledg drug class rel
infanc howev late-stag ngb pipelin phase ii develop
moreov three ngb launch bring total number ngb
market
figur na launch therapeut area
figur na launch highlight diseas
term approv new activ substanc na launch
oncolog drug percentag drug launch orphan design
continu rise diseas orphan drug also impact total number
subject includ trial na launch base one trial
seven na base phase ii trial indic acceler trial timelin
track statu launch uniform popul rare diseas
drug launch went track intend speed develop process
studi enrol size may smaller certain rare diseas orphan indic
regulatori shift also help eas lengthen develop timelin
complex late stage clinic trial stagnant sinc emphas oner
enrol process inher greater need outsourc solut
figur number subject launch na trial trial contain
fewer patient
divers faster-grow end market emerg biotechnolog compani often lack
financi resourc infrastructur conduct extens clinic trial complet
part develop process said smaller biotech compani
develop increasingli greater proport therapeut today compar larger
biotechnolog pharmaceut compani sinc sourc pipelin innov
shift meaning biotech repres pipelin opportun vs
dynam expect continu help drive greater adopt clinic
develop outsourc importantli increasingli focus custom sub-
segment particularli differenti biotech offer review
depth page expect sub-seg remain key pillar long-term
growth strategi target offer enabl grow exist core relationship among
smid biopharma penetr sub-seg
figur sourc pipelin innov shift increasingli toward biotech
healthi biotech fund environ base multipl metric track biotech
fund trend gain momentum ytd believ sustain robust trend
bode well particularli above-averag exposur faster-grow small-
mid-siz biotech compani overal fund level declin year-over-year
absolut invest remain elev averag indic still
multipl relev sourc fund virtual small mid-siz biotechnolog
compani summar note sourc fund data captur limit
scope transact thu multipl sourc like provid comprehens view
ventur capit fund accord data evaluatepharma ventur capit fund
declin billion albeit tough comp well
billion histor averag
biotech capit market accord bioworld fund public offer
includ ipo follow-on declin compar albeit absolut level
still well billion histor averag moreov year-to-d
februari fund level grown meaning also note
biotech ipo vs
larg pharma academia also sourc fund contribut
larger pharma conting also underappreci sourc fund view
biotech fund stem licens deal royalti stream partnership mileston
payment accord bioworld biotech increas
total transact moreov biotech deal bioworld defin licens
jv collabor therapeut compani increas total
deal importantli pharmaceut compani increasingli seek bulk
product develop pipelin oppos ration shift rational
compani remain key sourc fund small- mid-siz biotech compani
inher insul broader capit market activ
prolifer new complex therapeut immuno-oncolog therapi
recent year diseas modifi capabl also drive continu invest
biotech promis molecul broader capit market ventur capit larg
figur quarterli overal biotech fund includ public offer fund public biotechnolog compani
fund privat biotechnolog compani quarterli ytd billion
note public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant
debt offer right offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat
bioworld public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis
warrant debt offer right offer standard privat placement pipe institut offer regist stock privat includ financ privat firm
rise complex develop five everi
experiment compound enter preclin trial advanc human test
one ultim gain regulatori approv commerci rise cost develop
biotechspublic/otherpubl growth average fund compar fund averag averag billion follow on averag billion averag billion averag billion charl martineau pm univers toronto march
nearli sinc see figur financi impract sponsor
maintain redund develop team facil therefor biopharmaceut compani
increasingli reliant optim fix overhead cost shorten develop
timelin expand clinic trial manag capabl global
tuft center studi drug develop csdd credit suiss
meanwhil accord iqvia institut past decad aggreg time take
drug progress regulatori decis phase trial increas
sinc reach year vs year phase ii particular
seen notabl increas averag trial length past decad attribut
heighten complex grow number endpoint trial site countri subject
complex ultim drive durat cost stem part advanc
research technolog well new therapi biolog genet target
therapi cell gene therapi increasingli dire need address broader global
diseas threat oncolog orphan indic along heighten regulatori
protocol burdensom penalti non-compli
figur clinic trial therapeut class
figur cell gene therapi innov number
mani trial today rare diseas requir smaller stratifi patient pool
increas complex clinic trial target therapeut area prolong start-up time
 earli earli market market shareanti-fibrinolyticsseera gammaglobulinsanti-hyperlipidaemicsanti-coagulantsimmunosuppressantsm therapiesdermatologicalsanti-hypertensivessensori biolog pipelin project preclin -phase ab/proteinsbiosimilarscell/gen charl martineau pm univers toronto
slow backlog convers note industri constitu past
year view phenomenon underscor broader valu proposit drug
manufactur seek effici develop solut overal increas cost
complex drug develop speed market critic month delay result
estim million million lost revenu drive biopharmaceut compani
outsourc increas portion develop project order maxim effici
capit fix cost flexibl provid
greater scrutini price increasingli oner price competit
pressur drive biopharmaceut compani reduc fix cost shift
flexibl cost structur also increas focu simplifi histor complex
suppli chain streamlin vendor manag valu place qualiti
product reliabl time deliveri
price reimburs pressur govern third-parti payor patent expir
rise generic/biosimilar util chang product mix rise cost complianc
weigh biopharmaceut revenu profit increas import speed-
to-market lead biopharmaceut compani focu sale market later-
stage clinic develop well reli outsourc formul
manufactur function increas regulatori burden drive manufactur
cost higher support greater outsourc demand avoid consequ
manufactur develop qualiti issu lead drug shortag lost
figur biopharma model face pressur multipl front
strateg posit lead partner biotech arena target
biotech offer allow capit favor underli market shift wherebi
rate biotech spend growth meaning outpac larg pharma
biotech account new drug approv past five year
late-stag pipelin vs term exposur backlog
associ biotech custom vs prior biotech launch
compar favor rel known exposur across broader diversifi clinic cro
 syneo health icon plc see figur albeit biotech-
focus clinic provid medpac time expect biotech exposur expand
offer diversifi custom base larg pharma histor
domin revenu stream also contribut acceler organ revenu growth
inher faster grow custom cohort importantli biotech award
phase iib iv clinic trial inher less riski earlier develop trial
payer consolidationmco pbm consolidationcontinu rise afford genericsgener account prescript less develop market spendingpipelin replenish ratio fallsan accentur analysi show declin three-year averag pipelin replenish ratio price pressurepharma achiev mid-single-digit price increas trend expect continu follow year high-single-digit greater price increasesscrutini promot tacticsact inquiri regulatori bodi multipl tactic includ dtc advertis co-pay card patient assist programsdeclin treatment leadership positionaccentur report declin amount time treatment retain leadership posit market charl martineau pm univers toronto march
figur backlog mix highlight biotech exposur across cro peer group
note iclr biotech exposur base revenu exposur base backlog
exposur base new award
examin import emerg small biotech arena
accord iqvia institut emerg biopharma ebp compani defin compani
spend less million annual less million annual
revenu play increasingli pivot role drug develop landscap account
late-stag pipelin vs
figur late-stag pipelin compani size emerg biopharma play
meanwhil small mid-siz compani billion revenu
billion revenu experienc deterior market share past year
account pipelin respect
moreov larg pharma billion revenu pipelin drop pipelin
domin ebp faster-grow area like oncolog
orphan drug expect ebp share captur fuel overal outsourc demand reduc
need inher asset-light ebp compani partner larger counterpart
ultim bring drug develop cycl evidenc therapi
us launch ebp registr file compar
histor larg pharma compani bought licens vast major ebp novel
molecul commerci launch healthi fund environ continu
support ebp pursuit bring drug market addit na launch
deriv ebp patent vs acknowledg ebp continu
grow presenc drug develop landscap develop fill greater
number fda regulatori submiss bode well
figur new activ substanc launch
figur new activ substanc launch size
compani submit fda emerg biopharma compani
increasingli bring drug market
term financ previous mention page fund level declin
year-over-year absolut invest remain elev averag
indic still robust underli environ see figur biotech fund level
biotech compani year cash hand ultim support spend
resili potenti period lacklust fund
throughout drug develop process biotech compani often face uniqu challeng
includ leaner team tighter timelin like fewer resourc asset-light model
moreov conjunct run drug develop process biotech constitu often
also need priorit fundrais effort distinct factor mind biotech
custom typic requir increment support cro partner said smaller player
oftentim feel lost shuffl work larg global cro partner typic
funnel greater resourc perceiv higher-valu larg pharma custom
histor predomin focus larg pharma compani fuel growth howev
began acknowledg fundament market landscap shift on-going wherebi
capit flow meaning smaller biotech arena coincid
pullback fund larg pharma sponsor light evolv market dynam
recogn need transform model unveil newer target offer design
support inher asset-light biotech compani evidenc aforement
market trend today biotech compani becom increasingli import group across
drug develop landscap decis creat biotech-focus offer
posit well sustain above-market growth longer term
notabl appropri understood evolut drug develop market
embrac biotech constitu target offer compani decid
enhanc biotech effort despit temporarili weaker book relat
biotech model overhaul wherebi implement higher-touch model approach
compani earliest stage biotech life cycl sinc doubl
annual biotech-rel author first nine month result
short-term weak manag foresight execut renew offer
demonstr abil nimbl adapt evolv landscap invest aim
today biotech offer leverag sophist custom develop activ
includ earli identif novel molecul extens pre-trial consult advisori
engag custom goal posit prefer partner ahead
potenti new busi opportun order identifi novel molecul follow
fund flow biotech compani vc partner identifi
engag compani manner year two ahead phase ii trial task
typic assign team medic doctor discuss potenti develop program
biotech compani
figur util collabor earli engag approach enhanc posit across biotech life cycl
high-touch model enabl cro tailor solut need specif
biotech compani addit assign respons team biotech custom may
also benefit expertis strong global organ wealth medic
regulatori expertis well data analyt enabl custom scale trial
rapidli moreov execut leadership team also remain commit success
custom willing speak directli ceo ceo strengthen partnership
highlight area expertis
cell gene therapi broad therapeut expertis across cell gene therapi
develop focu adenovirus/aav lentiviru virus-bas immunotherapi
non-vir vector car-t cell cell-bas medicin product highlight regulatori
expertis key sourc differenti global team provid full end-to-end
regulatori support includ earli engag activ scientif advic rmat
author environment submiss dossier interact countri specif agenc
clinic trial applic ind impd author gap analysi protocol review global
submiss consult strateg regulatori consult clinic non-clin
consult moreov laboratori segment support comprehens solut
experi across variou cell gene therapi includ plasmid linear
encapsul nucleic acid base product car-t viral vector
importantli conduct cell gene therapi studi across multipl region
past five year
dermatolog also leader across dermatolog work larg
biopharma biotech medic devic academ organ expertis across
broad rang indic includ psoriasi atop dermat aesthet pemphigu
epidermolysi bullosa inflamm rare dermatolog condit global team
compris profession across emea north america asia pacif
latin america project manag serv key point
clinic oper supportlimit oper capabl molecules- support contract legal- creativ commerci construct payment- access kol pre-trial consult base similar molecules/tri term medic expert fill expertis gapsventur seed fundinginstitut fund cross-overtri defin rfp issuedtri launch- identif novel charl martineau pm univers toronto march
contact custom note conduct dermatolog trial includ
rare dermatolog diseas trial patient across site global
past five year
figur area expertis across dermatolog
nash/nafld competit field multipl studi on-going readi begin
acceler studi start-up highli import maxim enrol potenti
becom lead partner nash strong site relationship nash site
global databas experi fast enrol site highly-relev proprietari self-
report patient data respond self-report fatty-liv diseas
refin patient pathway effici diagnosi process max patient reach moreov
offer full-servic central lab support rapid biopsi logist prepar deep
understand medic regulatori requir well experi novel
imag techniqu manag liver biopsi notabl past five year
support studi involv patient across site
acceler enrol solut address key bottleneck across drug
develop continuum includ patient recruit studi start also provid
import sourc differenti rel peer innov solut util global
dedic site network research site locat across five contin
countri combin acurian databas fulli identifi consent inform
enabl faster site start-up reduct number site view
busi key differenti across increasingli import area focu biopharma
custom enhanc valu proposit therebi support new busi win
moreov may also offer stand-alone basi site patient access
provid diversifi revenu stream also offer addit mechan
develop new/exist custom relationship offer upsid estim
patient enrol one biggest pain point across drug develop
patient recruit complianc investig site among greatest obstacl
today particularli trial becom increasingli complex special orphan
diseas less us popul particip clinic trial
trial meet initi recruit difficulti patient recruit major caus
project delay singl largest sourc budget overrun repres signific
industri concern moreov biopharma constitu strive improv
recruit timelin also minim burden patients/sit well increas
context tradit studi plan predomin driven number site estim
achiev enrol wherebi site forecast expect patient enrol
particular locat biopharma constitu ad togeth enrol
expect denomin number potenti patient achiev target patient
popul forecast util diseas map well proprietari databas
estim access inform potenti elig patient
reduc overal reliabl enrol forecast ultim site feasibility/forecast
inaccur addit studi site like requir ad therebi increas
cost chang order ultim drug develop timelin
order address patient recruit challeng introduc acceler enrol
solut busi aim maxim patient deliveri predict central
recruit model uniqu strategi leverag at-scal matur site network strategi
conjunct data analyt acurian aim drive relev patient site
proprietari insight also note maintain dedic studi start-up team
extens recruit knowledg support enrol effort differ typic industri
protocol acceler enrol rate also reduc number
site requir essenti elimin non-enrol site note offer
stand-alone solut sell data directli biopharma constitu
importantli built platform variou acquisit includ five
transact see figur provid context around
valu major acquisit
figur invest patient enrol capabl
acurian acquir acurian patient recruit retent solut platform
defin number patient recruit gener popul base highli
predict enrol model model support fulli identifi data
million us household data million pre-screen individu includ
inform demograph self-report diseas contact inform select health
data moreov continu build databas pre-screen patient daili order
recruit patient gener trial lead local tailor recruit campaign incl
social media prescreen candid via call center on-line ask respond
consent relat health contact inform evalu refer patient person
research site
context histor reli upon de-identifi data public data sourc
provid approxim locat anonym patient therebi enabl
develop diseas heat map use select site area patient live recent
select iqvia im data scienc symphoni
increasingli focus pre-identifi data allow identifi specif site
anonym patient context access identifi inform enabl direct
view site patient provid meaning advantag site recruit aid
feasibl site select enrol
figur ppd identifi databas differenti rel cro util de-identifi pre-identifi data
also note acurian offer success patient engag retent program
consist three integr compon util constantli commun patient across
on-line offlin channel studi map proprietari mobil applic
track patient progress increas engag drive retent uniqu gamif
techniqu also provid valuabl inform exam test procedur
appoint appoint remind studi inform motiv messag acurian
also util mutli-channel patient messag wherebi autom messag platform
commun key studi inform patient via app email phone call text
messag lastli provid patient engag educ materi includ patient
welcom booklet greet thank-you card educ leaflet inform
touch-point effort reduc risk miss commun prevent
surpris may otherwis lead patient dissatisfact dropout also improv
complianc overal studi outcom
network variou acquisit past sever year
creat global site network scale variou acquisit includ radiant us-
focus synexu emea focus optim research oncology/vaccine-focus synarc
china latam western eu focus access million
patient across site network highlight current network
synexus/radi may synexu us-bas radiant integr creat
world largest site network oper synexu name synexu
global site network clinic research facil across us mexico
south america europ asia south africa also provid access million
world-wide patient network activ patient
phase studi across site us europ middl east africa asia-pacif
earli phase oncolog network also access global oncolog
site support presenc across increasingli import pipelin area note
oncolog footprint bolster acquisit optim research
said necessarili view ownership physic site product use
capit other industri abl develop less capit intens partnership
leverag cohes relationship would prefer still remain encourag
de-identifiedpre-identifiedidentifiedanonym diseas data genomics- trial registries- social media- consumer- geographic- insuranceapproxim locat ofspecif site withdirect view anonym patientsanonym patientssit patientstyp datapurposeuseassist select site area patient live heat map cluster patient locat anonym view diseas popul within site identifi data million us household million prescreen individu incl demograph self-report diseas contact inform select health data assist select site pre-identifi patient databasesdata set identifi site level assist site-to-pati recruitmenten direct access patient permiss contact patient directli aid feasibl site select enrol proven convers timelin charl martineau pm univers toronto
overarch integr enrol solut also leverag proprietari data
asset analyt note expect invest via
site network alreadi maintain suffici capac
break proprietari solut
within acceler enrol solut two offer patientadvantag
oncolog enrol enhanc highlight detail key offer
patientadvantag patientadvantag solut combin acurian synexu
servic order creat patient-cent approach clinic develop
aforement tradit plan method typic util site forecast identifi site
locat theoret abl recruit certain number patient ppd
patientadvantag revolution model move patient identif forefront
figur identifi potenti patient acurian highli predict
enrol model strateg send identifi particip site
locat move site start-up patient identif essenti elimin
low-perform site also deliv budget certainti time enrol broader
oncolog enrol enhanc pre-qualifi pre-negoti site
privat practic hospit system academ center
investig oncology-focus solut design augment exist
patient recruit tactic util just-in-tim methodolog approach
first engag pre-negoti site network patient
identifi activ given site importantli site activ
typic enrol patient within day also elimin non-enrol site
context oncolog site enrol gener take eight month averag
activ site site never enrol singl patient on-going
trial unlik meet enrol
integr global laboratori servic offer complement core clinic develop
servic busi offer gmp bioanalyt biomark vaccin central lab solut
sever oper central laboratori potenti esoter test
bioanalyt capabl maintain comprehens solut increment
patient site countri global enrol entir program took week two month shorter client expect significantli shorter two analog recent drug develop programsmap patient locationsselect patient-rich sitesgreat enrollmentstudi executionfirst subject radnom last subject random deliv fasterfirst site activ last site activ deliv fasterenrol period significantli shorter concurr studiesidentifi qualifi patient gener charl martineau pm univers toronto
advanc laboratori offer provid key competit advantag rel competitor
importantli laboratori servic augment organ revenu trend lab segment
continu outpac market growth compound-annual-growth-rate sinc vs market
dynam expect continu moreov expect laboratori servic also continu
support improv backlog burn rate notabl custom frequent cite ppd
laboratori servic key rational partner cro one-third biotech
win co-sel clinic develop lab servic demonstr inher busi
addit sever also maintain integr central laboratori offer
order augment overal clinic develop solut common adjac across
peer group discuss previous central lab support collect transport test
analysi clinic sampl safeti efficaci typic offer inclus test initi
test patient accept trial safeti efficaci test exploratori biomark
studi genom proteom metabolom central lab function integr
overal busi vs outsourc third-parti cro may offer earlier access clean data
timelin potenti cost save custom
refer central lab market broadli domin two lead constitu
labcorp covanc iqvia/quest diagnost joint ventur ownership split
solut covanc maintain share base revenu support trial
lab facil us switzerland singapor china well strateg
relationship bml japan meanwhil solut found march
second largest player central lab market share notabl iqvia quest
diagnost recent announc million commit expand north carolina facil
aim meet increas demand regulatori compliant genom test clinic
trial well provid translat servic notabl constitu includ icon plc
estim share central lab market well
current share accord analysi
estim third largest player across central laboratori market
approxim share support scientif employe advanc degre
forecast central lab market grow five-year compound-annual-growth-rate
expect busi unit grow above-market predic share gain smaller
constitu still highli fragment market
central lab clearli import compon servic offer highlight
also particip meaning advanc test servic market size
billion opportun estim grow high-singl low-doubl digit
rang annual market continu grow acceler pace predic need
intric refin laboratori test support develop increasingli
complex sophist therapeut importantli given increas test complex
advanc test busi maintain higher margin lower level capit intens
rel central lab standard diagnost test
notabl histor particip advanc test market albeit
limit capac rel central laboratori market exampl labcorp covanc offer
wide rang specialti esoter test conjunct core base diagnost
segment offer includ appli genom next-gen sequenc anatom
molecular patholog flow cytometri clinic immunoassay preclin exploratori
biomark develop solut also offer analyt test conjunct
quest diagnost base core diagnost unit includ genom bioanalyt
laboratori servic also highlight icon plc maintain small esoter test
busi includ flow cytometri gener profil
meanwhil offer robust advanc test platform includ bioanalyt
biomark gmp vaccin lab see detail compani overview pg
servic span entir clinic develop continuum advanc
laboratori servic support acceler growth rate across broader lab servic platform
mention previous expect growth five-year compound-annual-growth-rate
vs market growth
figur ppd advanc test span entir clinic develop continuum
proprietari preclaru portal also offer proprietari preclaru portal
client web/mobile-bas platform manag investig site deliv
inform relat patient registr streamlin ship send critic alert valu
send queri real-tim note labcorp covanc busi also maintain
compet extern face tool includ lablink xceller investig portal
internet-bas custom program allow custom review queri
clinic trial laboratori data near real-tim basi
geograph scope highlight china histor global
necessarili need presenc china compet success given slow legaci
drug approv cycl recent focu drug develop countri revers
dynam china becom increasingli import manag highlight
client cite strong lab busi china key rational choos
cro partner particular trial moreov expect expand
post-approvalregulatori file approvalsafeti surveillancevaccin labgmp labbiomark labbioanalyt labcentr labclin developmentearli developmentpreclin developmentphas iphas iiphas charl martineau pm univers toronto
presenc region open new lab offer bioanalyt biomark
vaccin servic lab build-out support exist partnership
chines hospit orient toward chronic ambulatori trial
boast oper margin total revenu estim
meaning industri averag seen figur sustain
heighten profit margin profil rel clinic cro peer rigor price disciplin
achiev stabl bid margin past five year moreov reduc
number contract modif cycl time sinc therebi also drive
reduct project cost overrun addit price disciplin also maintain dilig
focu product includ util resourc manag zero-bas
budget technolog invest drive effici robot process autom new erp
new bid system creation global hub invest high talent lower cost
geographi bulgaria india philippin mexico
notabl cro peer current maintain higher overal adjust oper margin
highlight charl river laboratori preclin busi model inher higher-
margin clinic outsourc model iqvia higher-margin technolog busi im
revenu ebit margin bolster ebitda margin well
note compar impact technolog offer rev post-approv servic
preclinical/post-approv lab servic revenu full servic smid biotech
focus symphoni data offer revenue meaning exposur central lab exposur capit
intens site network strategi central lab exposur commerci exposur revenu
posit bia admittedli predic meaning margin expans
stori compound earn growth encourag abil sustain above-market
margin aforement price disciplin product initi partial off-set
headcount growth support new busi win outlay sustain industri lead retent
rate bp benchmark well continu invest across laboratori
servic segment site network strategi importantli expect slight oper margin
expans bp lower depreci amort percentag revenu
partial off-set increment cost million relat new public compani cost
said still expect bp oper margin expans figur
frequent cite margin headwind across cro peer period basi relat invest
across employe base includ headcount growth support new busi retent
effort grown headcount sinc includ new hire
first nine month sustain impress margin profil point
abil appropri manag cost off-set necessari invest sustain growth
context service-ori busi employe base remain essenti asset
cro peer histor comment signific risk relat fail satisfi
custom like caus inappropri staf prematur accept
project order combat risk must continu recruit retain elit talent
figur headcount rise time strateg invest support growth
moreov remain impress heighten employe engag retent
rel industri benchmark demonstr higher margin profil expens
employe base three ten role fill intern career move per year
moreov averag tenur manag year project manag
turnov rate almost bp industri
unlev cash flow convers sinc capit deploy remain key
stori near term net debt ebitda follow ipo expect
like priorit debt pay target net leverag longer term see figur
debt pay expect also continu priorit invest across
core platform order help custom bend cost time curv develop
regard capit deploy includ organ invest strateg base
anticip return invest potenti also return capit sharehold
figur net debt ebitda trajectori
sinc invest cumul million across lab servic busi core
system clinic technolog help support above-market growth moreov
spent nearli billion highlight key acquisit figur
recommend work ytdppdpm cro charl martineau pm univers toronto march
note maintain signific focu across acceler enrol solut offer
see detail well real world evid data analyt capabl
figur ppd strateg billion spend sinc
mention previous cash flow convers sinc allow
continu invest busi sustain heighten growth context look ppd
histor cash flow gener three period see figur consid period
baselin year prior effort tighten work capit manag
meaning increas focu balanc sheet item particularli
work capit achiev near best-in-class cash flow convers rel
clinic cro peer steady-st work capit partial off-set increas capit
expenditur aforement cash invest drive growth go forward
expect capit expenditur percentag revenu decreas signific
initi behind partial off-set increas cash tax
figur gener million
earn outlook financi resourc
remind requir adopt account convent
impair compar rel histor result well across industri constitu
wherebi cro report dynam still uniform new standard context
provid metric basi order illustr year-over-year growth margin
provid result prior howev go forward
beyond refer incom sheet metric basi importantli continu
report book metric basi
review basi consolid revenu rose billion
growth clinic develop laboratori servic net servic revenu
respect well fall reimburs clinic develop servic growth
predic fall organ growth off-set bp
contribut bp fx benefit importantli weak across ppd clinic
develop busi predic biotech strategi shift wherebi
experienc meaning short term decreas new author revamp offer
therebi impact growth meanwhil ppd laboratori servic busi continu
perform well post organ growth pdd post ttm book-
to-bil backlog burn rate healthi metric view ebitda
margin expand bp basi vs
continu price disciplin intern effici initi
review consolid revenu rose billion
growth clinic develop laboratori servic net servic
revenu respect well bp headwind reimburs
acknowledg easi year-over-year comp across clinic develop busi
also view high-single-digit growth across segment indic traction
offer larger custom offer post ttm book-
to-bil backlog convers basi demonstr sustain
healthi book metric throughout moreov ebitda margin expand
bp price disciplin effici initi
outlook estim revenu rise billion predic
servic revenu growth rise reimburs servic revenu growth
driven rise ppd clinic develop servic laboratori
servic respect forecast achiev ttm book-to-bil
backlog burn rate basi
forecast gener million adjust ebitda ebitda
margin impli flat margin year-over-year new public compani cost investor
relat function sarbanes-oxley complianc director offic liabil insur off-set
reduct sg relat long-term incent compens program ltip
form manag compens replac stock-bas compens
exclud adjust ebitda metric follow ipo tax rate
share base million expect ep rise compar
longer term outlook longer term forecast achiev consolid
revenu compound-annual-growth-rate includ net servic revenu cagr
clinic develop laboratori servic segment respect moreov
expect bp underli ebitda margin expans predic
continu competit bid price disciplin well intern effici initi
vari year-to-year near-term expect pay debt therebi
support net incom growth longer term capit deploy like focus return
capit sharehold via share repurchas potenti dividend well
compani data credit suiss estim mm
compani data credit suiss estim mm
million cash reserv billion debt impli net debt posit
capit deploy effort near term primarili focus de-lever
expect reach net debt estim gener million
million cash flow oper respect
cash convers cycl day septemb rose day
june vs day averag year end decemb
septemb day sale outstand day sequenti deterior
june day payabl outstand day unchang
prior period
figur convers cycl million
compani data credit suiss estim mm
ppd ipo price per share februari price-to-earnings high
end rang base million common share includ green shoe
first day trade share price increas close day per share to-
date stock price increas vs importantli
current trade forward price-to-earnings ev/ebitda multipl respect
premium broader peer group includ clinic cro peer constitu
target price predic price-to-earnings ev/ebitda multipl
premium broader cro peer group respect strength across
underli market environ conjunct company-specif driver includ
acceler growth across biotech platform traction enrol solut
faster-grow laboratori servic unit continu drive enhanc book
growth visibl longer term
price-to-earnings ev/ebitda blue sky scenario predic
better anticip book across biotech acceler enrol solut
well faster growth across laboratori servic busi conjunct
strengthen underli market fundament
price-to-earnings ev/ebitda grey sky scenario predic
slight deterior underli market fundament compound slower anticip
book across biotech acceler enrol solut well slower
anticip growth laboratori servic busi
perspect crp valuat alreadi notabl elev reflect healthi fast-
announc core industri constitu point continu growth momentum
cro compani histor trade premium broader
pursuant cro index figur
fundament well
cro index includ lh iclr prxl sep cvd feb
look compar compani primarili focu global diversifi clinic
syneo health medpac hold also take account lead preclin
constitu charl river laboratori also play underli fundament
trend across broader landscap moreov includ labcorp hous covanc
drug develop sale albeit repres inher less relev comp given
exposur clinic laboratori market us cro peer group trade
price-to-earnings ev/ebitda multipl averag respect
price-to-earnings price-to-earnings average cro averagespxhistor averag histor averag averag cspriceupsid volrevenu cy average cy average cy average cy price-to-earnings cy ev/ebitda cy dividendtickerratingtargetdownsidepricecap research organizationsiqvia river manufactur organizationswest pharmaceut group ag laboratorieslaboratori corp charl martineau pm univers toronto march
next sever year
fluctuat spend forecast modest growth spend
result public
biopharmaceut player could neg affect invest could therebi also
neg affect demand outsourc develop servic regulatori macroeconom
pressur could also lead modest pace growth slower growth overal
medicin spend global turn would headwind cro revenu growth
investor pressur disappoint
lacklust biotechnolog fund environ fund vital import smaller
biotechnolog compani seek busi compani
affect mani factor control includ broader market
condit interest rate well rel attract biopharmaceut
industri overal biotech fund fell year-over-year absolut
invest remain elev well preced ten-year averag nonetheless
prolong pronounc deterior biotech fund environ could present
signific risk futur revenu profit
consolid consolid biopharmaceut compani caus
fluctuat outsourc contract affect overal product pipelin potenti cut
 budget may consequ effect outsourc partner extent custom
overlap pipelin ration moreov factor result decreas number
potenti custom may also advers affect potenti enabl custom
negoti better price discount term servic less favor
cancel project delay chang scope shift pipelin contract
cancel project delay client pipelin repriorit neg affect revenu
growth profit particularli relat sizeabl cancel chang
scope strateg relationship resourc staff might easili redeploy
project moreov major servic contract base fix price fix
unit price servic set limit amount charg servic variat
time progress larg contract potenti drive materi advers effect result
oper
custom concentr top custom repres revenu
repres meaning top account custom concentr outsiz exposur particular
custom inher caus increment volatil note acknowledg singl
custom repres revenu inher prone
higher custom concentr given size scale larg pharmaceut compani
regulatori shift drug develop commerci process chang
govern regul fda foreign agenc equival drug develop
process includ health care reform risk could affect demand cro servic unfavor
regulatori chang less stringent expedit drug approv procedur could affect
overal demand regulatori expertis increasingli harsh regulatori requir
continu drive demand outsourc servic
drug price scrutini compress biopharma return invest drug price
come increasingli scrutini past coupl year polit pressur call
broader drug price reform drive conserv price increas year-over-year
basi inher compress biopharmaceut compani return invest given
drug refer brand drug price increas histor high-single-
digit rang last year brand price increas mid-single-digit rang price increas
track previou year experi dynam continu
pressur profit expect like drive higher hurdl rate pipelin opportun
biopharmaceut compani potenti delay trial start ration
complet less desir market environ
leverag hamper liquid restrict invest estim billion
debt balanc sheet follow initi public offer impli net leverag
current level indebted could impair busi limit abil obtain
addit debt equiti financ work capit acquisit well limit abil
continu invest across platform
potenti implic exposur china remain limit today
could potenti disrupt busi oper within countri patient
longer regularli attend check-up relat clinic trial note septemb
acquir synarc global site network busi bioclinica aim expand
compani footprint china latin america moreov spread meaning
global could impact busi oper addit countri well
foreign currenc fluctuat inher natur hedg constantli
evolv global market expos currenc fluctuat signific portion
sale deriv oversea unfavor exchang rate dollar reduc
revenu cash flow caus varianc report result
capit deploy relat miscu inabl captur target synergi futur
acquisit integr relat headwind acquisition-rel miscu could weigh
investor sentiment financi result
manag team compris veteran biopharmaceut industri
sever top execut come larg pharmaceut counterpart ceo cfo-pfiz
coo-bristol myer ceo david simmon serv chairman ceo sinc
view encourag longer term orient strategi posit
compani well re-ent public market also highlight william sharbaugh also
extens experi serv role sinc also
encourag extens experi remaind execut manag
nameposit agebiographi david simmonschairman serv chairman ceo sinc may prior join serv variou role pfizer inc recent presid emerg market establish product busi unit current serv board director albani molecular research inc edelman engin llc well board advisor carnegi mellon univers tepper school busi william april serv chief oper offic prior serv variou role recent vice presid global develop oper well variou role research develop manufactur qualiti assur sale merck co sculli cfo treasur assist secretari serv chief offic treasur assist secretari sinc may prior serv variou role pfizer inc includ chief commerci offic essenti health busi unit region presid europ establish product donovan serv chief account offic sinc june prior serv variou role deloitt touch novemb may includ audit assur partner septemb may thakralevp chief commerci thakral serv evp chief commerci offic sinc novemb previous serv evp global head biotech juli novemb prior mr thakral serv gener manag global life scienc busi unit gerson lehrman group march june judd hartmanevp gener counsel hartman serv gener counsel sinc juli june also appoint chief administr offic addit continu serv gener counsel prior join mr hartman serv vice presid legal affair anker coal group inc coal mine compani fikri evp global fikri serv execut vice presid global laboratori sinc june prior join mr fikri serv variou role septemb may includ vice presid gener manag oncolog companion diagnost ronald garrowevp chief hr garrow serv execut vice presid chief human resourc offic sinc juli prior join mr garrow serv variou role belk juli juli includ chief human resourc offic prior join belk mr garrow work mastercard march juli david johnstonevp global head clinic johnston serv evp global head clinic develop sinc octob juli septemb mr johnston serv evp global head laboratori prior join mr johnston work labcorp april june serv senior vice presid global head clinic trial busi karen kaucicpresid evidera chief medic kaucic serv variou leadership posit sinc decemb current serv chief medic offic presid evidera prior join ms kaucic held posit oncolog clinic develop medimmun astrazeneca june decemb charl martineau pm univers toronto march
figur quarterli ep basi million except per share amount
histor servic revenu out-of-pocket gener incom expens incom expens equiti loss unconsolid loss unconsolid affili net incom common share gener servic total incom attribut common gener total incom attribut common charl martineau pm univers toronto march
figur quarterli revenu million
histor develop differ account revenu revenu mix develop growthclin develop revenu revenu new businessbegin backlog ex new busi ex servic backlog ex new servic convers charl martineau pm univers toronto march
figur annual ep basi million except per share amount
servic revenu out-of-pocket gener incom expens incom expens equiti loss unconsolid loss unconsolid affili net incom net common share out-of-pocket gener net servic total out-of-pocket gener charl martineau pm univers toronto march
figur annual revenu million
histor develop differ account revenu revenu mix develop growthclin develop revenu revenu new businessbegin backlog ex new busi ex servic backlog ex new servic convers charl martineau pm univers toronto march
figur balanc sheet million
sheetcash cash receiv unbil servic current current equip asset portion long-term current debt long-term paid-in comprehens stockhold liabil sharehold ebitda debt ltm charl martineau pm univers toronto march
figur statement million
histor net debt issuanc cost debt defer incom sale receiv unbil servic current tax payabl accru expens oper assets/li cash provid oper properti sale properti busi contribut paid receiv sale cash use invest repurchas exercis stock debt issuanc employe stock capit special dividend cash use financ foreign exchang chang cash cash equival restrict cash cash equival restrict cash equival restrict cash begin cash equival restrict cash end flow charl martineau pm univers toronto march
peer global databas captur uniqu inform compani within credit
suiss coverag univers base relationship compani custom
supplier competitor databas built research analyst insight regard
relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb peer
compani mention price
labcorp america lh
